{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:56:50Z","timestamp":1776070610603,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Mephedrone is a largely abused psychostimulant. It elicits the release of monoamines via the high affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). Stereoselective metabolic reactions are involved in the inactivation and the elimination of its chemical structure. However, during these processes, several structures are generated and some of them have been reported to be still pharmacologically active. In this study 1) we have newly synthetized several putative mephedrone metabolites, 2) compared their activity at monoamine transporters, 3) generated quantitative structure activity relationships, and 4) exploited the chemical structure of the putative metabolites to screen a urine sample from a drug user and dissect mephedrone metabolism. We have found that most of the tested metabolites are weak inhibitors of monoamine transporters and that all of them are more potent at DAT and NET in comparison to SERT. The only exception is represented by the COOH-metabolite which shows no pharmacological activity at all three monoamine transporters. The enantioselectivity of mephedrone and its metabolites is present mainly at SERT, with only minor effects at DAT and NET being introduced when the \u03b2-keto group is reduced to an OH-group. Importantly, while at DAT the putative metabolites did not show changes in inhibitory potencies, but rather changes in their substrate\/blocker profile, at SERT they showed mainly changes in inhibitory potencies. Molecular modeling suggests that the hydrophobic nature of a specific SERT subpocket may be involved in such loss of affinity. Finally, the assessment of the putative metabolites in one urine sample of mephedrone user displayed two previously uncharacterized metabolites, 4-COOH-nor-mephedrone (4-COOH-MC) and dihydro-4- nor-mephedrone (dihydro-4-MC). These results confirm and expand previous studies highlighting the importance of the stereochemistry in the pharmacodynamics of phase-1 metabolites of mephedrone, established their structure-activity relationships at DAT, NET and SERT and pave the way for a systematic dissection of mephedrone metabolic routes. Given the number of structures found having residual and modified pharmacological profiles, these findings may help in understanding the complex subjective effects of administered mephedrone. Moreover, the dissection of mephedrone metabolic routes may help in developing new therapies for treating psychostimulants acute intoxications.<\/jats:p>","DOI":"10.3389\/fphar.2021.654061","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T07:12:53Z","timestamp":1617952373000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity in vitro"],"prefix":"10.3389","volume":"12","author":[{"given":"Marco","family":"Niello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cintulov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Raithmayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Holy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"J\u00e4ntsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Colas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard F.","family":"Ecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko D.","family":"Mihovilovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/164_2018_178","article-title":"Neuropharmacology of synthetic cathinones","volume":"252","author":"Baumann","year":"2018","journal-title":"Handb Exp. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/npp.2015.260","article-title":"Abuse of new psychoactive substances: threats and solutions","volume":"41","author":"Baumann","year":"2016","journal-title":"Neuropsychopharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1111\/bph.13030","article-title":"Quantitative structure-activity relationship analysis of the pharmacology ofpara-substituted methcathinone analogues","volume":"172","author":"Bonano","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18350-6","article-title":"A new approach towards biomarker selection in estimation of human exposure to chiral chemicals: a case study of mephedrone","volume":"7","author":"Castrignan\u00f2","year":"2017","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0169-328x(02)00177-8","article-title":"Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain","volume":"103","author":"Chinta","year":"2002","journal-title":"Mol. Brain Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.tins.2004.03.011","article-title":"DAncing past the DAT at a DA synapse","volume":"27","author":"Cragg","year":"2004","journal-title":"Trends Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.tips.2011.08.005","article-title":"Cytochrome P450 enzymes in the brain: emerging evidence of biological significance","volume":"32","author":"Ferguson","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/3-540-29784-7_5","article-title":"Currents in neurotransmitter transporters","volume":"175","author":"Gerstbrein","year":"2006","journal-title":"Handb Exp. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1111\/bph.12628","article-title":"The preclinical pharmacology of mephedrone; not just MDMA by another name","volume":"171","author":"Green","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bph.12951","article-title":"Stereochemistry of mephedrone Neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats","volume":"172","author":"Gregg","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/mol.118.114793","article-title":"Functional selectivity and partial efficacy at the monoamine transporters: a unified model of allosteric modulation and amphetamine-induced substrate release","volume":"95","author":"Hasenhuetl","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"e0217377","DOI":"10.1371\/journal.pone.0217377","article-title":"A structural model of the human serotonin transporter in an outward-occluded state","volume":"14","author":"Hellsberg","year":"2018","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/s0140-6736(16)30258-6","article-title":"Mephedrone use is increasing in london","volume":"387","author":"Hockenhull","year":"2016","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fphar.2020.00673","article-title":"Cell-based radiotracer binding and uptake inhibition assays: a comparison of in vitro methods to assess the potency of drugs that target monoamine transporters","volume":"11","author":"Ilic","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/dta.313","article-title":"Cathinone derivatives: a review of their chemistry, pharmacology and toxicology","volume":"3","author":"Kelly","year":"2011","journal-title":"Drug Test Anal"},{"key":"B16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1021\/jm00227a004","article-title":"Quantitative structure-activity relationships. 2. A mixed approach, based on hansch and free-wilson analysis","volume":"19","author":"Kubinyi","year":"1976","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.toxlet.2015.10.025","article-title":"Metabolic profile of mephedrone: identification of nor-mephedrone conjugates with dicarboxylic acids as a new type of xenobiotic phase II metabolites","volume":"240","author":"Linhart","year":"2016","journal-title":"Toxicol. Lett."},{"key":"B19","first-page":"187","article-title":"The detoxification enzyme systems","volume":"3","author":"Liska","year":"1998","journal-title":"Altern. Med. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2018.06.018","article-title":"The psychostimulant (\u00b1)-cis-4,4\u2032-dimethylaminorex (4,4\u2032-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters","volume":"138","author":"Maier","year":"2018","journal-title":"Neuropharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.neuro.2012.08.003","article-title":"Effects of synthetic cathinones contained in \u201cbath salts\u201d on motor behavior and a functional observational battery in mice","volume":"33","author":"Marusich","year":"2012","journal-title":"Neurotoxicology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuropharm.2018.12.032","article-title":"Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter","volume":"148","author":"Mayer","year":"2019","journal-title":"Neuropharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_63","article-title":"Application of a combined approach to identify new psychoactive street drugs and decipher their mechanisms at monoamine transporters","volume":"32","author":"Mayer","year":"","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1111\/bph.13547","article-title":"Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters","volume":"173","author":"Mayer","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00216-010-3636-5","article-title":"Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry","volume":"397","author":"Meyer","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"B27","first-page":"406","article-title":"Drug-metabolizing cytochrome P450s in the brain","volume":"27","author":"Miksys","year":"2002","journal-title":"J. Psychiatry Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.sbi.2019.03.011","article-title":"Insights into the mechanism and pharmacology of neurotransmitter sodium symporters","volume":"54","author":"Navratna","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"107615","DOI":"10.1016\/j.neuropharm.2019.04.021","article-title":"Para-trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter","volume":"161","author":"Niello","year":"2019","journal-title":"Neuropharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tips.2020.04.006","article-title":"Allosteric modulation of neurotransmitter transporters as a therapeutic strategy","volume":"41","author":"Niello","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/cpt.1417","article-title":"Dose\u2010response pharmacological study of mephedrone and its metabolites: pharmacokinetics, serotoninergic effects, and impact of CYP2D6 genetic variation","volume":"106","author":"Olesti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/s2215-0366(18)30305-5","article-title":"The growing problem of mephedrone use in Warsaw, Poland, 2010-18","volume":"5","author":"Ordak","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/dta.1369","article-title":"In vitrometabolism studies on mephedrone and analysis of forensic cases","volume":"5","author":"Pedersen","year":"2013","journal-title":"Drug Test. Anal."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1021\/acschemneuro.7b00212","article-title":"Stereoselective differences between the reinforcing and motivational effects of cathinone-derived 4-methylmethcathinone (mephedrone) in self-administering rats","volume":"8","author":"Philogene-Khalid","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.12.005","article-title":"Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter","volume":"147","author":"Reith","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"B36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/jpet.111.188946","article-title":"Studies of the biogenic amine transporters. 14. Identification of low-efficacy \u201cpartial\u201d substrates for the biogenic amine transporters","volume":"341","author":"Rothman","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/npp.2014.325","article-title":"\u2018Second-Generation' mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function","volume":"40","author":"Saha","year":"2015","journal-title":"Neuropsychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/bph.13043","article-title":"Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues","volume":"172","author":"Sakloth","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00213-010-2070-x","article-title":"Mephedrone (4-methylmethcathinone; \u2018meow meow'): chemical, pharmacological and clinical issues","volume":"214","author":"Schifano","year":"2011","journal-title":"Psychopharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","article-title":"Amphetamines, new psychoactive drugs and the monoamine transporter cycle","volume":"36","author":"Sitte","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B41","unstructured":"World drug report2016"},{"key":"B42","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1124\/jpet.104.080101","article-title":"Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs","volume":"313","author":"Wee","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.654061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T07:12:58Z","timestamp":1617952378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.654061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":42,"alternative-id":["10.3389\/fphar.2021.654061"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.654061","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"654061"}}